bioAffinity Technologies, Inc. BIAF
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 11.77% | -15.15% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 11.77% | -15.15% | |||
| Cost of Revenue | 17.14% | 3.17% | |||
| Gross Profit | -0.05% | -38.95% | |||
| SG&A Expenses | -11.82% | 6.73% | |||
| Depreciation & Amortization | -46.20% | -7.44% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -2.48% | 5.05% | |||
| Operating Income | 7.80% | -15.30% | |||
| Income Before Tax | 7.29% | -15.83% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 7.29% | -15.72% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 7.29% | -15.72% | |||
| EBIT | 7.80% | -15.30% | |||
| EBITDA | 6.54% | -16.23% | |||
| EPS Basic | 20.27% | -15.10% | |||
| Normalized Basic EPS | 20.27% | -15.21% | |||
| EPS Diluted | 20.27% | -15.10% | |||
| Normalized Diluted EPS | 20.27% | -15.21% | |||
| Average Basic Shares Outstanding | 16.28% | 0.57% | |||
| Average Diluted Shares Outstanding | 16.28% | 0.57% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||